Predictive value of EGFR amplification and EGFRvIII mutation in EGFR-targeted therapy for recurrent glioblastoma: a systematic review.
Dylan Evans, Joanne Voisey, Jennifer H Gunter et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated the predictive value of EGFR amplification and EGFRvIII mutation for EGFR-targeted therapy in adults with recurrent glioblastoma (GBM). Analyzing 12 studies involving 565 patients, the review found no consistent survival benefit associated with these biomarkers, with median overall survival ranging from 5.7 to 10.3 months. The findings suggest that these alterations should not guide treatment decisions.
Key findings
- Median overall survival for patients ranged from 5.7 to 10.3 months.
- Progression-free survival varied from 1.7 to 6.0 months across studies.
- No consistent survival benefit was observed from EGFR-targeted therapies.
- The evidence is derived from heterogeneous, single-arm studies.
Why it matters
Understanding the predictive value of biomarkers like EGFR amplification and EGFRvIII mutation is crucial for optimizing treatment strategies in recurrent glioblastoma. This review highlights the need for reliable markers to guide therapy decisions.
What to keep in mind
The review is based on heterogeneous, single-arm studies, which limits the ability to assess treatment response reliably.